ID   NCI-H157
AC   CVCL_0463
SY   NCl-H157; NCI H157; H157; H-157; NCI-157; NCIH157DM
DR   BTO; BTO:0002283
DR   CLO; CLO_0037032
DR   EFO; EFO_0003118
DR   MCCL; MCC:0000360
DR   ArrayExpress; E-MTAB-783
DR   ATCC; CRL-5802
DR   BioSample; SAMN03151855
DR   BioSample; SAMN03471738
DR   cancercelllines; CVCL_0463
DR   CCRID; 1101HUM-PUMC000113
DR   ChEMBL-Cells; CHEMBL3307706
DR   ChEMBL-Targets; CHEMBL614783
DR   CLS; 300387
DR   Cosmic; 722053
DR   Cosmic; 724867
DR   Cosmic; 801588
DR   Cosmic; 844816
DR   Cosmic; 852006
DR   Cosmic; 876171
DR   Cosmic; 877258
DR   Cosmic; 903569
DR   Cosmic; 911847
DR   Cosmic; 917987
DR   Cosmic; 929971
DR   Cosmic; 930486
DR   Cosmic; 932921
DR   Cosmic; 934546
DR   Cosmic; 953987
DR   Cosmic; 949208
DR   Cosmic; 980960
DR   Cosmic; 1028954
DR   Cosmic; 1032432
DR   Cosmic; 1146881
DR   Cosmic; 1219061
DR   Cosmic; 1239910
DR   Cosmic; 1320185
DR   Cosmic; 2560227
DR   Cosmic; 2648437
DR   Cosmic; 2668267
DR   Cosmic; 2668329
DR   DepMap; ACH-000921
DR   GEO; GSM62967
DR   GEO; GSM108815
DR   GEO; GSM108816
DR   GEO; GSM253365
DR   GEO; GSM434267
DR   GEO; GSM784238
DR   GEO; GSM794274
DR   IARC_TP53; 495
DR   IARC_TP53; 28242
DR   IARC_TP53; 28453
DR   IGRhCellID; H157GEO
DR   KCB; KCB 200814YJ
DR   KCLB; 90157
DR   LINCS_LDP; LCL-1596
DR   PRIDE; PXD002556
DR   Progenetix; CVCL_0463
DR   PubChem_Cell_line; CVCL_0463
DR   Wikidata; Q54907822
RX   PubMed=1311061;
RX   PubMed=1563005;
RX   PubMed=3940644;
RX   PubMed=6148444;
RX   PubMed=6270685;
RX   PubMed=6272398;
RX   PubMed=6713399;
RX   PubMed=7972006;
RX   PubMed=8626706;
RX   PubMed=8806092;
RX   PubMed=9649128;
RX   PubMed=10536175;
RX   PubMed=11005564;
RX   PubMed=11369051;
RX   PubMed=12068308;
RX   PubMed=12820372;
RX   PubMed=16187286;
RX   PubMed=19472407;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20557307;
RX   PubMed=20624269;
RX   PubMed=22961666;
RX   PubMed=23381221;
RX   PubMed=25120651;
RX   PubMed=26361996;
RX   PubMed=29681454;
RX   PubMed=30038707;
RX   PubMed=31803961;
WW   https://www.atcc.org/en/support/technical-support/faqs/cross-contamination-of-atcc-crl-5802-and-atcc-crl-5860
WW   https://www.atcc.org/en/support/technical-support/faqs/misidentified-cell-lines-atcc-crl-5802-and-atcc-crl-5860
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. NCI-H157 and NCI-H1264 have been shown to be identical.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00412.
CC   Doubling time: 53 hours (Note=In RPMI 1640 + 10% FBS), 90 hours (Note=In ACL-3 + BSA) (PubMed=3940644); 20.8 hours (PubMed=29681454).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Homozygous (PubMed=30038707; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (PubMed=1311061; PubMed=12068308; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu35fs*8 (c.102_103insT) (c.103_104insT); Zygosity=Heterozygous (PubMed=10536175; PubMed=20557307; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Heterozygous (PubMed=1311061; PubMed=10536175; PubMed=20557307; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: ATCC; CRL-5802; true.
CC   Discontinued: KCLB; 90157; probable.
ST   Source(s): ATCC; CCRID; CLS
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D12S391: 20
ST   D13S317: 12
ST   D16S539: 12,13
ST   D18S51: 13,15
ST   D19S433: 11,13
ST   D21S11: 32
ST   D2S1338: 21,22
ST   D3S1358: 17,18
ST   D5S818: 10,13
ST   D6S1043: 17,24
ST   D7S820: 12
ST   D8S1179: 14,16
ST   FGA: 22,23
ST   Penta D: 2.2
ST   Penta E: 7
ST   TH01: 7,9
ST   TPOX: 6,12
ST   vWA: 15
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_3970 ! NCI-H1264
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   PubMed=1311061;
RA   Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D.,
RA   Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D.,
RA   Gazdar A.F.;
RT   "p53 gene mutations in non-small-cell lung cancer cell lines and their
RT   correlation with the presence of ras mutations and clinical
RT   features.";
RL   Oncogene 7:171-180(1992).
//
RX   PubMed=1563005;
RA   Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W.;
RT   "Neuromedin B is present in lung cancer cell lines.";
RL   Cancer Res. 52:2732s-2736s(1992).
//
RX   PubMed=3940644;
RA   Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.;
RT   "Growth of cell lines and clinical specimens of human non-small cell
RT   lung cancer in a serum-free defined medium.";
RL   Cancer Res. 46:798-806(1986).
//
RX   PubMed=6148444; DOI=10.1093/jnci/73.4.801;
RA   Morstyn G., Russo A., Carney D.N., Karawya E., Wilson S.H.,
RA   Mitchell J.B.;
RT   "Heterogeneity in the radiation survival curves and biochemical
RT   properties of human lung cancer cell lines.";
RL   J. Natl. Cancer Inst. 73:801-807(1984).
//
RX   PubMed=6270685; DOI=10.1073/pnas.78.7.4591;
RA   Cuttitta F., Rosen S.T., Gazdar A.F., Minna J.D.;
RT   "Monoclonal antibodies that demonstrate specificity for several types
RT   of human lung cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:4591-4595(1981).
//
RX   PubMed=6272398; DOI=10.1126/science.6272398;
RA   Moody T.W., Pert C.B., Gazdar A.F., Carney D.N., Minna J.D.;
RT   "High levels of intracellular bombesin characterize human small-cell
RT   lung carcinoma.";
RL   Science 214:1246-1248(1981).
//
RX   PubMed=6713399;
RA   Rosen S.T., Mulshine J.L., Cuttitta F., Fedorko J., Carney D.N.,
RA   Gazdar A.F., Minna J.D.;
RT   "Analysis of human small cell lung cancer differentiation antigens
RT   using a panel of rat monoclonal antibodies.";
RL   Cancer Res. 44:2052-2061(1984).
//
RX   PubMed=7972006; DOI=10.1073/pnas.91.23.11045;
RA   Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P.,
RA   Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H.,
RA   Harris C.C.;
RT   "Mutations and altered expression of p16INK4 in human cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
//
RX   PubMed=8626706; DOI=10.1074/jbc.271.19.11477;
RA   Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M.,
RA   Grimley C., Battey J., Mulshine J.L., Cuttitta F.;
RT   "Insulin-like growth factor expression in human cancer cell lines.";
RL   J. Biol. Chem. 271:11477-11483(1996).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=9649128; DOI=10.1038/bjc.1998.361;
RA   Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.;
RT   "Paracrine effects of hepatocyte growth factor/scatter factor on
RT   non-small-cell lung carcinoma cell lines.";
RL   Br. J. Cancer 77:2162-2170(1998).
//
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0;
RA   Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.;
RT   "Molecular cytogenetic analysis of non-small cell lung carcinoma by
RT   spectral karyotyping and comparative genomic hybridization.";
RL   Cancer Genet. Cytogenet. 125:87-99(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=12820372;
RA   Bergqvist M., Brattstrom D., Gullbo J., Hesselius P., Brodin O.,
RA   Wagenius G.;
RT   "p53 status and its in vitro relationship to radiosensitivity and
RT   chemosensitivity in lung cancer.";
RL   Anticancer Res. 23:1207-1212(2003).
//
RX   PubMed=16187286; DOI=10.1002/ijc.21491;
RA   Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D.,
RA   Gazdar A.F., Lam S., MacAulay C., Lam W.L.;
RT   "High resolution analysis of non-small cell lung cancer cell lines by
RT   whole genome tiling path array CGH.";
RL   Int. J. Cancer 118:1556-1564(2006).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
//
RX   PubMed=20624269; DOI=10.1186/1756-9966-29-75;
RA   Du L.-Q., Schageman J.J., Irnov I., Girard L., Hammond S.M., Minna J.D.,
RA   Gazdar A.F., Pertsemlidis A.;
RT   "MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells
RT   and suggests a possible pathological relationship between SCLCs and
RT   NSCLCs.";
RL   J. Exp. Clin. Cancer Res. 29:75.1-75.12(2010).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=23381221; DOI=10.3892/or.2013.2266;
RA   Suzuki M., Shiraishi K., Eguchi A., Ikeda K., Mori T., Yoshimoto K.,
RA   Ohba Y., Yamada T., Ito T., Baba Y., Baba H.;
RT   "Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small
RT   cell lung cancer.";
RL   Oncol. Rep. 29:1308-1314(2013).
//
RX   PubMed=25120651; DOI=10.3892/ol.2014.2234;
RA   Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K.,
RA   Shibata H., Ito T., Baba Y., Baba H.;
RT   "Aberrant methylation and silencing of IRF8 expression in non-small
RT   cell lung cancer.";
RL   Oncol. Lett. 8:1025-1030(2014).
//
RX   PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003;
RA   Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C.,
RA   Daub H.;
RT   "Comparative proteome analysis across non-small cell lung cancer cell
RT   lines.";
RL   J. Proteomics 130:1-10(2016).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=30038707; DOI=10.18632/oncotarget.25642;
RA   Du L.-Q., Zhao Z.-Z., Suraokar M.B., Shelton S.S., Ma X.-Y., Hsiao T.-H.,
RA   Minna J.D., Wistuba I.I., Pertsemlidis A.;
RT   "LMO1 functions as an oncogene by regulating TTK expression and
RT   correlates with neuroendocrine differentiation of lung cancer.";
RL   Oncotarget 9:29601-29618(2018).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//